RU2012123148A - Новые анти-il-13 антитела и их использование - Google Patents
Новые анти-il-13 антитела и их использование Download PDFInfo
- Publication number
- RU2012123148A RU2012123148A RU2012123148/10A RU2012123148A RU2012123148A RU 2012123148 A RU2012123148 A RU 2012123148A RU 2012123148/10 A RU2012123148/10 A RU 2012123148/10A RU 2012123148 A RU2012123148 A RU 2012123148A RU 2012123148 A RU2012123148 A RU 2012123148A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- subject
- host cell
- cell
- human
- Prior art date
Links
- 238000000034 method Methods 0.000 claims abstract 38
- 210000004027 cell Anatomy 0.000 claims abstract 28
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 claims abstract 15
- 102000019207 human interleukin-13 Human genes 0.000 claims abstract 15
- 210000004962 mammalian cell Anatomy 0.000 claims abstract 14
- 241000699802 Cricetulus griseus Species 0.000 claims abstract 7
- 210000001672 ovary Anatomy 0.000 claims abstract 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 5
- 210000004408 hybridoma Anatomy 0.000 claims abstract 4
- 208000006673 asthma Diseases 0.000 claims 8
- 238000001802 infusion Methods 0.000 claims 8
- 238000002347 injection Methods 0.000 claims 8
- 239000007924 injection Substances 0.000 claims 8
- 206010039085 Rhinitis allergic Diseases 0.000 claims 3
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 206010012434 Dermatitis allergic Diseases 0.000 claims 2
- 102000003816 Interleukin-13 Human genes 0.000 claims 2
- 108090000176 Interleukin-13 Proteins 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000024711 extrinsic asthma Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000010659 intrinsic asthma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
1. Анти-IL-13 антитело, которое специфически связывается с IL-13 человека, где указанное анти-IL-13 антитело конкурирует или связывается с тем же самым эпитопом, что и антитело, продуцированное гибридомой 228В/С-1, имеющей АТСС номер РТА-5657 для связывания с IL-13 человека.2. Анти-IL-13 антитело по п.1, которое специфически связывается с IL-13 человека, где указанное анти-IL-13 антитело получено способом, включающим этап экспрессирования анти-IL-13 антитела из клетки-хозяина.3. Анти-IL-13 антитело по п.2, где указанный способ дополнительно включает шаг очистки антитела из указанной клетки-хозяина.4. Анти-IL-13 антитело по п.2, где указанная клетка-хозяин является клеткой млекопитающего.5. Анти-IL-13 антитело по п.4, где указанная клетка млекопитающего является клеткой яичников китайского хомячка (СНО).6. Анти-IL-13 антитело по п.1, где указанное анти-IL-13 антитело связывается с эпитопом, включающим аминокислотную последовательность ESLINVSG (SEQ ID NO:18) или аминокислотную последовательность YCAALESLINVS (SEQ ID NO:19).7. Анти-IL-13 антитело по п.6, которое специфически связывается с IL-13 человека, где указанное анти-IL-13 антитело получено способом, включающим этап экспрессирования анти-IL-13 антитела из клетки-хозяина.8. Анти-IL-13 антитело по п.6, где указанный способ дополнительно включает шаг очистки антитела из указанной клетки-хозяина.9. Анти-IL-13 антитело по п.6, где указанная клетка-хозяин является клеткой млекопитающего.10. Анти-IL-13 антитело по п.6, где указанная клетка млекопитающего является клеткой яичников китайского хомячка (СНО).11. Анти-IL-13 антитело, которое специфически связывается с IL-13 человека, где указанное анти-IL-13 антитело представляет собой гуманизированное антитело, со�
Claims (50)
1. Анти-IL-13 антитело, которое специфически связывается с IL-13 человека, где указанное анти-IL-13 антитело конкурирует или связывается с тем же самым эпитопом, что и антитело, продуцированное гибридомой 228В/С-1, имеющей АТСС номер РТА-5657 для связывания с IL-13 человека.
2. Анти-IL-13 антитело по п.1, которое специфически связывается с IL-13 человека, где указанное анти-IL-13 антитело получено способом, включающим этап экспрессирования анти-IL-13 антитела из клетки-хозяина.
3. Анти-IL-13 антитело по п.2, где указанный способ дополнительно включает шаг очистки антитела из указанной клетки-хозяина.
4. Анти-IL-13 антитело по п.2, где указанная клетка-хозяин является клеткой млекопитающего.
5. Анти-IL-13 антитело по п.4, где указанная клетка млекопитающего является клеткой яичников китайского хомячка (СНО).
6. Анти-IL-13 антитело по п.1, где указанное анти-IL-13 антитело связывается с эпитопом, включающим аминокислотную последовательность ESLINVSG (SEQ ID NO:18) или аминокислотную последовательность YCAALESLINVS (SEQ ID NO:19).
7. Анти-IL-13 антитело по п.6, которое специфически связывается с IL-13 человека, где указанное анти-IL-13 антитело получено способом, включающим этап экспрессирования анти-IL-13 антитела из клетки-хозяина.
8. Анти-IL-13 антитело по п.6, где указанный способ дополнительно включает шаг очистки антитела из указанной клетки-хозяина.
9. Анти-IL-13 антитело по п.6, где указанная клетка-хозяин является клеткой млекопитающего.
10. Анти-IL-13 антитело по п.6, где указанная клетка млекопитающего является клеткой яичников китайского хомячка (СНО).
11. Анти-IL-13 антитело, которое специфически связывается с IL-13 человека, где указанное анти-IL-13 антитело представляет собой гуманизированное антитело, содержащее CDRs антитела, продуцированные гибридомой 228В/С-1, имеющей АТСС номер РТА-5657.
12. Анти-IL-13 антитело по п.11, которое специфически связывается с IL-13 человека, где указанное анти-IL-13 антитело получено способом, включающим этап экспрессирования анти-IL-13 антитела из клетки-хозяина.
13. Анти-IL-13 антитело по п.11, где указанный способ дополнительно включает шаг очистки антитела из указанной клетки-хозяина.
14. Анти-IL-13 антитело по п.11, где указанная клетка-хозяин является клеткой млекопитающего.
15. Анти-IL-13 антитело по п.11, где указанная клетка млекопитающего является клеткой яичников китайского хомячка (СНО).
16. Анти-IL-13 антитело, которое специфически связывается с IL-13 человека, где указанное анти-IL-13 антитело содержит аминокислотную последовательность антитела, продуцированного гибридомой 228В/С-1, имеющей АТСС номер РТА-5657.
17. Анти-IL-13 антитело по п.16, которое специфически связывается с IL-13 человека, где указанное анти-IL-13 антитело получено способом, включающим этап экспрессирования анти-IL-13 антитела из клетки-хозяина.
18. Анти-IL-13 антитело по п.16, где указанный способ дополнительно включает шаг очистки антитела из указанной клетки-хозяина.
19. Анти-IL-13 антитело по п.16, где указанная клетка-хозяин является клеткой млекопитающего.
20. Анти-IL-13 антитело по п.16, где указанная клетка млекопитающего является клеткой яичников китайского хомячка (СНО).
21. Анти-IL-13 антитело, которое специфически связывается с IL-13 человека, где указанное анти-IL-13 антитело, содержит антигенсвязывающие участки, полученные из антитела по п.16.
22. Анти-IL-13 антитело по п.21, которое специфически связывается с IL-13 человека, где указанное анти-IL-13 антитело получено способом, включающим этап экспрессирования анти-IL-13 антитела из клетки-хозяина.
23. Анти-IL-13 антитело по п.21, где указанный способ дополнительно включает шаг очистки антитела из указанной клетки-хозяина.
24. Анти-IL-13 антитело по п.21, где указанная клетка-хозяин является клеткой млекопитающего.
25. Анти-IL-13 антитело по п.21, где указанная клетка млекопитающего является клеткой яичников китайского хомячка (СНО).
26. Фармацевтическая композиция для использования в качестве лекарственного средства, содержащая терапевтически эффективное количество анти-IL-13 антитела по любому из пп.1-25.
27. Способ лечения астматических симптомов у субъекта, включающий введение субъекту эффективного количества анти-IL-13 антитела по любому из пп.1-25.
28. Способ по п.27, где анти-IL-13 антитело вводят путем ингаляции, болюсным инъецированием или инфузией.
29. Способ по п.27, где субъектом является человек.
30. Способ снижения астматических симптомов у субъекта с астматическими симптомами, включающий введение субъекту эффективного количества анти-IL-13 антитела по любому из пп.1-25.
31. Способ по п.30, где анти-IL-13 антитело вводят путем ингаляции, болюсным инъецированием или инфузией.
32. Способ по п.30, где субъектом является человек.
33. Способ лечения воспалительного заболевания у субъекта, включающий введение субъекту эффективного количества анти-IL-13 антитела по любому из пп.1-25.
34. Способ по п.33, где анти-IL-13 антитело вводят путем ингаляции, болюсным инъецированием или инфузией.
35. Способ по п.33, где субъектом является человек.
36. Способ лечения идиопатического пневмофиброза или воспалительного и фиброзного легочного заболевания у субъекта, включающий введение субъекту эффективного количества анти-IL-13 антитела по любому из п.п.1-25.
37. Способ по п.36, где анти-IL-13 антитело вводят путем ингаляции, болюсным инъецированием или инфузией.
38. Способ по п.36, где субъектом является человек.
39. Способ ингибирования продуцирования IgE антител у субъекта, включающий введение субъекту эффективного количества анти-IL-13 антитела по любому из п.п.1-25.
40. Способ по п.39, где анти-IL-13 антитело вводят путем ингаляции, болюсным инъецированием или инфузией.
41. Способ по п.39, где субъектом является человек.
42. Способ по п.39, где ингибирование продуцирования IgE антитела предназначено для предупреждения бронхиальной астмы, для предупреждения аллергических ринитов, для предупреждения аллергических дерматитов, для предупреждения анафилаксии, для лечения бронхиальной астмы, для лечения аллергических ринитов, для лечения крапивницы, или для лечения аллергических дерматитов.
43. Способ по п.42, где анти-IL-13 антитело вводят путем ингаляции, болюсным инъецированием или инфузией.
44. Способ по п.42, где субъектом является человек.
45. Способ лечения IL-13 опосредованного расстройства у субъекта, включающий введение субъекту анти-IL-13 антитела, по любому из пп.1-25, где IL-13 опосредованное расстройство - это аллергическая астма (атопическая астма), неаллергическая астма, аллергические риниты, атопические дерматиты, аллергические коньюнктивиты, экзема, крапивница, пищевые аллергии, хроническое обструктивное легочное заболевание, неспецифический язвенный колит, респираторно-синцитальная вирусная (RSV инфекция) инфекция, увеиты, склеродерма или остеопороз.
46. Способ по п.45, где анти-IL-13 антитело вводят путем ингаляции, болюсным инъецированием или инфузией.
47. Способ по п.45, где субъектом является человек.
48. Способ лечения астмы у субъекта, включающий введение терапевтически эффективного количества анти-IL-13 антитела, по любому из пп.1-25.
49. Способ по п.48, где анти-IL-13 антитело вводят путем ингаляции, болюсным инъецированием или инфузией.
50. Способ по п.48, где субъектом является человек.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53213003P | 2003-12-23 | 2003-12-23 | |
US60/532,130 | 2003-12-23 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006122037/10A Division RU2487887C2 (ru) | 2003-12-23 | 2004-12-23 | Новые анти-il 13 антитела и их использование |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2020106818A Division RU2752833C1 (ru) | 2003-12-23 | 2020-02-13 | Новые анти-il13 антитела и их использование |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2012123148A true RU2012123148A (ru) | 2013-12-10 |
Family
ID=34738751
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006122037/10A RU2487887C2 (ru) | 2003-12-23 | 2004-12-23 | Новые анти-il 13 антитела и их использование |
RU2012123148/10A RU2012123148A (ru) | 2003-12-23 | 2012-06-05 | Новые анти-il-13 антитела и их использование |
RU2020106818A RU2752833C1 (ru) | 2003-12-23 | 2020-02-13 | Новые анти-il13 антитела и их использование |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006122037/10A RU2487887C2 (ru) | 2003-12-23 | 2004-12-23 | Новые анти-il 13 антитела и их использование |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2020106818A RU2752833C1 (ru) | 2003-12-23 | 2020-02-13 | Новые анти-il13 антитела и их использование |
Country Status (24)
Country | Link |
---|---|
US (10) | US7674459B2 (ru) |
EP (6) | EP1703893B1 (ru) |
JP (5) | JP4851944B2 (ru) |
KR (5) | KR101280338B1 (ru) |
CN (4) | CN102993302B (ru) |
AT (1) | ATE552850T1 (ru) |
AU (1) | AU2004308494B2 (ru) |
CA (2) | CA2550651C (ru) |
CY (2) | CY1113009T1 (ru) |
DK (4) | DK2805728T3 (ru) |
ES (4) | ES2775204T3 (ru) |
FI (1) | FI3718564T3 (ru) |
HK (3) | HK1108007A1 (ru) |
HR (3) | HRP20231569T1 (ru) |
HU (1) | HUE049161T2 (ru) |
IL (2) | IL176042A (ru) |
LT (2) | LT3718564T (ru) |
MX (1) | MX361174B (ru) |
PL (4) | PL1703893T3 (ru) |
PT (3) | PT2805728T (ru) |
RU (3) | RU2487887C2 (ru) |
SG (4) | SG10201900535UA (ru) |
SI (4) | SI3718564T1 (ru) |
WO (2) | WO2005062967A2 (ru) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7883704B2 (en) * | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
CA2550651C (en) * | 2003-12-23 | 2018-01-23 | Tanox, Inc. | Novel anti-il 13 antibodies and uses thereof |
US20050186146A1 (en) * | 2004-02-12 | 2005-08-25 | Nektar Therapeutics | Interleukin-13 antagonist powders, spray-dried particles, and methods |
DK1716181T3 (da) | 2004-02-19 | 2010-03-01 | Genentech Inc | CDR-reparerede antistoffer |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
DE602005025525D1 (de) | 2004-11-17 | 2011-02-03 | Amgen Inc | Vollständige humane monoklonale antikörper gegen il-13 |
GB2430883B (en) * | 2005-09-30 | 2008-03-19 | Cambridge Antibody Tech | Interleukin-13 antibody composition |
US20070202106A1 (en) * | 2005-10-06 | 2007-08-30 | Baylor Research Institute | Compositions and methods for the treatment of cancer |
US20070237763A1 (en) * | 2005-10-06 | 2007-10-11 | Baylor Research Institute | Compositions and methods for the treatment of cancer |
WO2007045477A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Human antibodies against il-13 and therapeutic uses |
RU2432362C2 (ru) | 2005-11-30 | 2011-10-27 | Эбботт Лэборетриз | Моноклональные антитела и их применения |
GB0600488D0 (en) * | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
AU2007209202A1 (en) * | 2006-01-24 | 2007-08-02 | Domantis Limited | Ligands that bind IL-4 and/or IL-13 |
EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
ES2817756T3 (es) * | 2006-09-08 | 2021-04-08 | Abbvie Bahamas Ltd | Proteínas de unión a interleuquina-13 |
AU2008205512B2 (en) | 2007-01-16 | 2014-06-12 | Abbvie Inc. | Methods for treating psoriasis |
TW200848429A (en) * | 2007-04-23 | 2008-12-16 | Wyeth Corp | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
WO2008140455A1 (en) * | 2007-05-15 | 2008-11-20 | Tanox, Inc. | Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies |
US8183982B2 (en) | 2007-08-14 | 2012-05-22 | Infineon Technologies Ag | System including reply signal that at least partially overlaps request |
JP5641599B2 (ja) * | 2007-08-24 | 2014-12-17 | 学校法人慶應義塾 | 腫瘍細胞による免疫抑制の解除剤とそれを用いた抗腫瘍剤 |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
EP2274333A4 (en) | 2008-03-18 | 2011-06-15 | Abbott Lab | PROCESS FOR TREATING PSORIASIS |
NZ601815A (en) * | 2008-03-31 | 2014-10-31 | Genentech Inc | Compositions and methods for treating and diagnosing asthma |
MX2011001909A (es) | 2008-08-20 | 2011-03-21 | Centocor Ortho Biotech Inc | Anticuerpos anti-interleucina-13 modificados, composiciones, metodos y usos. |
CA2734905A1 (en) | 2008-09-03 | 2010-03-11 | Jenny M. Bostrom | Multispecific antibodies |
KR20110092328A (ko) * | 2008-11-26 | 2011-08-17 | 글락소 그룹 리미티드 | Il-13에 결합하는 리간드 |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
CN102946906B (zh) | 2010-04-23 | 2015-07-15 | 弗·哈夫曼-拉罗切有限公司 | 生产异源多聚体蛋白质 |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
MY188365A (en) | 2010-12-16 | 2021-12-06 | Genentech Inc | Diagnosis and treatments relating to th2 inhibition |
EP3604339B1 (en) | 2011-01-14 | 2021-03-10 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
RU2013140685A (ru) | 2011-02-04 | 2015-03-10 | Дженентек, Инк. | ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
JP2014510730A (ja) | 2011-03-16 | 2014-05-01 | サノフイ | デュアルv領域抗体様タンパク質の使用 |
EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
SG10201602654SA (en) | 2011-10-03 | 2016-05-30 | Moderna Therapeutics Inc | Modified nucleosides,nucleotides,and nucleic acids,and uses thereof |
RU2665810C2 (ru) * | 2011-10-31 | 2018-09-04 | Дженентек, Инк. | Содержащие антитела составы |
KR101483335B1 (ko) | 2011-11-01 | 2015-01-15 | 울산대학교 산학협력단 | 골 손실 진단 마커로서의 피브리노겐의 용도 |
CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
MX370486B (es) * | 2012-03-27 | 2019-12-16 | Genentech Inc | Composiciones, métodos y usos para asistir en el diagnóstico, pronóstico y tratamiento de la fibrosis pulmonar idiopática. |
AU2013243950A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
IN2014DN10889A (ru) * | 2012-07-13 | 2015-09-11 | Univ Pennsylvania | |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
AU2013381687A1 (en) | 2013-03-12 | 2015-09-24 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
CA2905223A1 (en) * | 2013-04-05 | 2014-10-09 | Genentech, Inc. | Anti-il-4 antibodies and bispecific antibodies and uses thereof |
BR112016004413A2 (pt) | 2013-09-13 | 2017-10-17 | Genentech Inc | composições, preparação de anticorpo e método de purificação de um polipeptídeo recombinante e de tratamento de um distúrbio |
BR112016004437A2 (pt) | 2013-09-13 | 2017-10-17 | Genentech Inc | métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) * | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
WO2015127405A2 (en) | 2014-02-21 | 2015-08-27 | Genentech, Inc. | Anti-il-13/il-17 bispecific antibodies and uses thereof |
BR112016023238A2 (pt) * | 2014-04-11 | 2017-10-17 | Novartis Ag | processos de tratamento seletivo de asma usando antagonistas de il-13 |
WO2015195758A1 (en) * | 2014-06-18 | 2015-12-23 | Medimmune, Llc | Cell culture methods and media comprising n-acetylcysteine |
WO2016073794A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
MX2017005930A (es) | 2014-11-05 | 2017-06-30 | Genentech Inc | Metodo de produccion de proteinas de cadena doble en bacterias. |
JP6929771B2 (ja) | 2014-11-10 | 2021-09-01 | ジェネンテック, インコーポレイテッド | 抗インターロイキン−33抗体及びその使用 |
CN107109494B (zh) | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Il-33介导型疾病的治疗方法和诊断方法 |
WO2016149276A1 (en) | 2015-03-16 | 2016-09-22 | Genentech, Inc. | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
EP3286227A2 (en) | 2015-04-24 | 2018-02-28 | F. Hoffmann-La Roche AG | Multispecific antigen-binding proteins |
EP3286315B1 (en) | 2015-04-24 | 2021-05-26 | F. Hoffmann-La Roche AG | Methods of identifying bacteria comprising binding polypeptides |
SI3528838T1 (sl) | 2016-09-23 | 2023-10-30 | F. Hoffmann-La Roche Ag | Uporabe IL-13 antagonistov za zdravljenje atopijskega dermatitisa |
EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
CA3051700A1 (en) | 2017-02-10 | 2018-08-16 | Genentech, Inc. | Anti-tryptase antibodies, compositions thereof, and uses thereof |
WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
WO2018195388A1 (en) * | 2017-04-21 | 2018-10-25 | Kindred Biosciences, Inc. | Il4/il13 receptor molecule for veterinary use |
US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
CN109776677B (zh) * | 2017-11-15 | 2023-11-03 | 尚华科创投资管理(江苏)有限公司 | 一种人源化抗il-13抗体及其制备方法和应用 |
CN113101364B (zh) | 2018-05-29 | 2023-12-01 | 康诺亚生物医药科技(成都)有限公司 | 一种自免疫抑制剂的开发和应用 |
EP3866924A4 (en) * | 2018-06-29 | 2022-07-06 | Krystal Biotech, Inc. | COMPOSITIONS AND METHODS OF ANTIBODY DELIVERY |
US20210220471A1 (en) * | 2018-07-13 | 2021-07-22 | Memorial Sloan Kettering Cancer Center | Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer |
US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
WO2020180727A1 (en) | 2019-03-06 | 2020-09-10 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer |
CN113597328A (zh) | 2019-03-21 | 2021-11-02 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
EP3966244A1 (en) * | 2019-05-09 | 2022-03-16 | F. Hoffmann-La Roche AG | Methods of making antibodies |
US20200352958A1 (en) * | 2019-05-10 | 2020-11-12 | The Trustees Of The University Of Pennsylvania | Methods And Compositions For Targeting Retinoic Acid For Solid Tumor Immunotherapy |
CA3154522A1 (en) | 2019-10-15 | 2021-04-22 | Christopher Carl Frye | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
CN115605507A (zh) | 2020-03-13 | 2023-01-13 | 基因泰克公司(Us) | 抗白介素-33抗体及其用途 |
TW202317191A (zh) | 2021-07-16 | 2023-05-01 | 美商德米拉股份有限公司 | 用於治療異位性皮炎之il-13抗體 |
TW202323291A (zh) | 2021-08-13 | 2023-06-16 | 美商德米拉股份有限公司 | 用於治療異位性皮膚炎之il-13抗體 |
IL311027A (en) | 2021-09-15 | 2024-04-01 | Dermira Inc | IL-13 inhibitors for the treatment of PRURIGO NODULARIS |
WO2023130010A1 (en) | 2021-12-30 | 2023-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
US20230357381A1 (en) * | 2022-04-26 | 2023-11-09 | Novartis Ag | Multispecific antibodies targeting il-13 and il-18 |
Family Cites Families (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
DE3127674A1 (de) | 1981-07-14 | 1983-02-24 | Rheinmetall GmbH, 4000 Düsseldorf | Verfahren und vorrichtung zum belegen einer zielflaeche mit munition |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
DE68921982T4 (de) | 1988-06-14 | 1996-04-25 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5359037A (en) * | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
WO1990005183A1 (en) * | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US5011778A (en) * | 1989-05-23 | 1991-04-30 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies |
AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
CZ283050B6 (cs) | 1989-12-20 | 1997-12-17 | Schering Corporation | Polypeptid, jeho subsekvence a jejich použití |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
EP0521985B1 (en) | 1990-03-20 | 1997-09-24 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
CA2092323A1 (en) | 1990-10-01 | 1992-04-02 | George Y. Wu | Targeting viruses and cells for selective internalization by cells |
EP0553244B8 (en) | 1990-10-05 | 2005-06-08 | Celldex Therapeutics, Inc. | Targeted immunostimulation with bispecific reagents |
AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
ES2178635T3 (es) | 1990-11-09 | 2003-01-01 | Stephen D Gillies | Inmunoconjugados de citoquinas. |
ES2054601T3 (es) * | 1991-03-29 | 1996-04-01 | Sanofi Sa | Proteina con actividad de tipo citoquina, adn recombinante codante para esta proteina, celulas y microorganismos transformados. |
HUT66753A (en) | 1991-04-26 | 1994-12-28 | Surface Active Ltd | Novel antibodies and methods for their use |
CA2103064A1 (en) | 1991-05-14 | 1992-11-15 | George Y. Wu | Targeted delivery of genes encoding immunogenic proteins |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
CA2103371C (en) | 1991-06-05 | 2003-09-16 | George Y. Wu | Targeted delivery of genes encoding secretory proteins |
US5994514A (en) * | 1991-08-14 | 1999-11-30 | Genentech, Inc. | Immunoglobulin variants |
US5965709A (en) * | 1991-08-14 | 1999-10-12 | Genentech, Inc. | IgE antagonists |
US6329509B1 (en) * | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
WO1993014188A1 (en) | 1992-01-17 | 1993-07-22 | The Regents Of The University Of Michigan | Targeted virus |
AU3658093A (en) | 1992-02-10 | 1993-09-03 | Seragen, Inc. | Desensitization to specific allergens |
AU3737893A (en) | 1992-03-05 | 1993-10-05 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
WO1993020221A1 (en) | 1992-04-03 | 1993-10-14 | Young Alexander T | Gene therapy using targeted viral vectors |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
US5318564A (en) | 1992-05-01 | 1994-06-07 | Hemostatic Surgery Corporation | Bipolar surgical snare and methods of use |
ES2136664T3 (es) | 1992-06-09 | 1999-12-01 | Hoppe Ag | Sistema de cierre y conjunto de cerradura. |
US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5596072A (en) * | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
CN1085953A (zh) * | 1992-08-21 | 1994-04-27 | 先灵公司 | 人白细胞介素13 |
JPH07508179A (ja) | 1992-08-21 | 1995-09-14 | シェリング・コーポレーション | ヒトインターロイキン−13 |
EP0749475A4 (en) | 1992-08-26 | 1997-05-07 | Harvard College | USE OF THE CYTOKIN IP-10 AS AN ANTI-TUMOR AGENCY |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
WO1994008598A1 (en) | 1992-10-09 | 1994-04-28 | Advanced Tissue Sciences, Inc. | Liver reserve cells |
EP0911413A3 (en) | 1992-12-03 | 2000-11-15 | Genzyme Corporation | Minimal adenovirus-based gene therapy vector |
US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
CN1127351C (zh) * | 1993-09-02 | 2003-11-12 | 达特茅斯学院理事 | 诱导抗原特异性t细胞耐受的方法 |
RU2162711C2 (ru) * | 1993-09-07 | 2001-02-10 | Смитклайн Бичам Корпорейшн | Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4 |
EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
GB9415379D0 (en) * | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
IT1270662B (it) * | 1994-10-13 | 1997-05-07 | Applied Research Systems | Antagonista della interleuchina-1 |
US5705154A (en) * | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
US6037453A (en) * | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
US6518061B1 (en) * | 1995-03-15 | 2003-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
ES2317646T3 (es) | 1995-09-08 | 2009-04-16 | Genzyme Corporation | Vectores aav mejorados para terapia genica. |
CA2238080C (en) | 1995-10-23 | 2012-03-13 | Amrad Operations Pty. Ltd. | A novel haemopoietin receptor and genetic sequences encoding same |
US6911530B1 (en) * | 1995-10-23 | 2005-06-28 | Amrad Operations, Pty., Ltd. | Haemopoietin receptor and genetic sequences encoding same |
FR2742156A1 (fr) | 1995-12-06 | 1997-06-13 | Sanofi Sa | Polypeptide recepteur de l'il-13 |
RO123028B1 (ro) | 1996-02-09 | 2010-07-30 | Abbott Laboratories (Bermuda) Ltd. | Anticorpi umani, care leagă tnf alpha uman |
US7078494B1 (en) * | 1996-03-01 | 2006-07-18 | Genetics Institute, Llc | Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding |
US6664227B1 (en) * | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
US5710023A (en) | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
KR20030096450A (ko) | 1996-03-22 | 2003-12-31 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 고사 유도 분자 ⅱ |
WO1997047742A1 (en) | 1996-06-12 | 1997-12-18 | Smithkline Beecham Corporation | Hr-1 receptor |
WO1998010638A1 (en) | 1996-09-10 | 1998-03-19 | Amrad Operations Pty. Ltd. | Therapeutic molecules |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
PT942968E (pt) | 1996-12-03 | 2008-03-27 | Amgen Fremont Inc | Anticorpos totalmente humanos que se ligam ao egfr |
US6743604B1 (en) * | 1996-12-13 | 2004-06-01 | Smithkline Beecham Corporation | Substances and their uses |
GB9625899D0 (en) * | 1996-12-13 | 1997-01-29 | Glaxo Group Ltd | Substances and their uses |
KR20000070034A (ko) | 1997-01-10 | 2000-11-25 | 아스트루 마이클 제이 | 항 cd40l 화합물로 신염성 루푸스를 치료하는 방법 |
WO1998031394A2 (en) * | 1997-01-22 | 1998-07-23 | Board Of Regents, The University Of Texas System | Tissue factor methods and compositions for coagulation and tumor treatment |
AU742045B2 (en) | 1997-04-14 | 2001-12-13 | Amgen Research (Munich) Gmbh | Novel method for the production of anti-human antigen receptors and uses thereof |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6642051B1 (en) | 1997-10-21 | 2003-11-04 | Targeted Genetics Corporation | Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors |
CA2309541C (en) | 1997-11-03 | 2011-01-11 | Human Genome Sciences, Inc. | Vegi, an inhibitor of angiogenesis and tumor growth |
US6576232B1 (en) * | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
US6482403B1 (en) | 1998-05-29 | 2002-11-19 | Heska Corporation | Caniney IL-13 immunoregulatory proteins and uses thereof |
US6299875B1 (en) * | 1998-06-04 | 2001-10-09 | Panacea Pharmaceuticals, Llc | Methods to block IGE binding to cell surface receptors of mast cells |
US6222971B1 (en) | 1998-07-17 | 2001-04-24 | David Slobodin | Small inlet optical panel and a method of making a small inlet optical panel |
GB9820014D0 (en) | 1998-09-14 | 1998-11-04 | Cancer Res Campaign Tech | Receptor antagonists and uses thereof |
DE19848026A1 (de) | 1998-10-17 | 2000-04-20 | Bayer Ag | Verfahren zur Herstellung von Bis(4-hydroxyaryl)alkanen |
US7553487B2 (en) * | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
BR9916209A (pt) | 1998-12-14 | 2001-12-26 | Genetics Inst | Cadeia de receptor de citocina |
US6567436B1 (en) | 1999-01-26 | 2003-05-20 | California Institute Of Technology | Opto-electronic oscillators having optical resonators |
AU2750800A (en) | 1999-02-01 | 2000-08-18 | Amgen Canada Inc. | Materials and methods to inhibit hodgkin and reed sternberg cell growth |
JP2003511019A (ja) * | 1999-10-06 | 2003-03-25 | ザ ペン ステート リサーチ ファウンデーション | Il13変異体 |
AU1599301A (en) | 1999-11-11 | 2001-06-06 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Modulating IL-13 activity using mutated IL-13 molecules that are antagonists or agonists of IL-13 |
US7422376B2 (en) | 1999-12-07 | 2008-09-09 | Molex Incorporated | Self-contained fiber optic connector module |
EP1270595B1 (en) | 2000-03-03 | 2008-07-23 | Kyowa Hakko Kogyo Co., Ltd. | Anti ccr4 antibody and its fragment |
CN1323812A (zh) | 2000-05-16 | 2001-11-28 | 上海博德基因开发有限公司 | 一种新的多肽——人白细胞介素-13(il-13)受体11和编码这种多肽的多核苷酸 |
WO2002033073A1 (fr) | 2000-10-20 | 2002-04-25 | Chugai Seiyaku Kabushiki Kaisha | Anticorps agoniste degrade |
EP2027867A1 (en) | 2000-10-20 | 2009-02-25 | Genetics Institute, LLC | Method and composition for inhibition of tumor growth and enhancing an immune response |
PT1449850E (pt) * | 2001-08-31 | 2011-02-02 | Kyowa Hakko Kirin Co Ltd | Anticorpos humanos enxertados em rdc¿s e fragmentos desses anticorpos |
US6908963B2 (en) * | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
EP1578912A4 (en) | 2001-10-26 | 2007-12-26 | Centocor Inc | IL-13 MUTEIN PROTEINS, ANTIBODIES, COMPOSITIONS, METHODS AND USES |
CA2466492A1 (en) | 2001-11-07 | 2003-05-15 | Cytos Biotechnology Ag | Antigen arrays presenting il-5, il-13 or eotaxin for treatment of allergic eosinophilic diseases |
US7541040B2 (en) * | 2001-12-04 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Serivces | Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
US20030170724A1 (en) * | 2002-03-08 | 2003-09-11 | Anderson David C. | Methods of identifying target polypeptides |
WO2003075859A2 (en) * | 2002-03-08 | 2003-09-18 | Rigel Pharmaceuticals, Inc. | COMPOUNDS THAT MODULATE PROCESSES ASSOCIATED WITH IgE PRODUCTION AND METHODS AND KITS FOR IDENTIFYING AND USING THE SAME |
AU2003223497A1 (en) * | 2002-04-05 | 2003-10-27 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
ATE503233T1 (de) | 2002-06-14 | 2011-04-15 | Us Gov Health & Human Serv | Verfahren zur behandlung und prävention von kolitis, an der il-13 und nk-t zellen beteiligt sind |
US7374894B2 (en) * | 2002-07-16 | 2008-05-20 | Rigel Pharmaceuticals, Inc. | Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein |
US20060147417A1 (en) | 2002-08-30 | 2006-07-06 | Claire Ashman | Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use |
CA2496948A1 (en) | 2002-08-30 | 2004-03-11 | Glaxo Group Limited | Il-14 vaccine for the treatment of asthma and atopic disorders |
EP1572946B1 (en) * | 2002-09-06 | 2012-03-14 | Amgen, Inc. | Therapeutic human anti-il-1r1 monoclonal antibody |
EP1592776A4 (en) | 2003-02-01 | 2008-06-04 | Tanox Inc | ANTI-HUMAN IGE ANTIBODIES WITH HIGH AFFINITY |
DK1471057T3 (da) * | 2003-04-25 | 2006-05-15 | Actimis Pharmaceuticals Inc | Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2 |
GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
CA2550651C (en) * | 2003-12-23 | 2018-01-23 | Tanox, Inc. | Novel anti-il 13 antibodies and uses thereof |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
GB2430883B (en) | 2005-09-30 | 2008-03-19 | Cambridge Antibody Tech | Interleukin-13 antibody composition |
WO2007045477A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Human antibodies against il-13 and therapeutic uses |
WO2008140455A1 (en) | 2007-05-15 | 2008-11-20 | Tanox, Inc. | Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies |
NZ601815A (en) | 2008-03-31 | 2014-10-31 | Genentech Inc | Compositions and methods for treating and diagnosing asthma |
MY188365A (en) | 2010-12-16 | 2021-12-06 | Genentech Inc | Diagnosis and treatments relating to th2 inhibition |
-
2004
- 2004-12-23 CA CA2550651A patent/CA2550651C/en active Active
- 2004-12-23 CN CN201210299210.6A patent/CN102993302B/zh active Active
- 2004-12-23 EP EP04815562A patent/EP1703893B1/en active Active
- 2004-12-23 ES ES14164624T patent/ES2775204T3/es active Active
- 2004-12-23 KR KR1020067014859A patent/KR101280338B1/ko active IP Right Grant
- 2004-12-23 SI SI200432525T patent/SI3718564T1/sl unknown
- 2004-12-23 CN CN2004800386571A patent/CN1973053B/zh active Active
- 2004-12-23 PT PT141646240T patent/PT2805728T/pt unknown
- 2004-12-23 RU RU2006122037/10A patent/RU2487887C2/ru active
- 2004-12-23 AU AU2004308494A patent/AU2004308494B2/en active Active
- 2004-12-23 HU HUE14164624A patent/HUE049161T2/hu unknown
- 2004-12-23 KR KR1020147003706A patent/KR101627588B1/ko active IP Right Grant
- 2004-12-23 PL PL04815562T patent/PL1703893T3/pl unknown
- 2004-12-23 DK DK14164624.0T patent/DK2805728T3/da active
- 2004-12-23 EP EP04815598A patent/EP1711528B1/en active Active
- 2004-12-23 HR HRP20231569TT patent/HRP20231569T1/hr unknown
- 2004-12-23 DK DK04815562.6T patent/DK1703893T3/da active
- 2004-12-23 ES ES10179775.1T patent/ES2533084T3/es active Active
- 2004-12-23 EP EP14164624.0A patent/EP2805728B1/en active Active
- 2004-12-23 PT PT04815562T patent/PT1703893E/pt unknown
- 2004-12-23 EP EP10179775.1A patent/EP2332575B1/en active Active
- 2004-12-23 SI SI200432492T patent/SI2805728T1/sl unknown
- 2004-12-23 AT AT04815562T patent/ATE552850T1/de active
- 2004-12-23 SG SG10201900535UA patent/SG10201900535UA/en unknown
- 2004-12-23 SG SG200901976-1A patent/SG151296A1/en unknown
- 2004-12-23 US US10/583,926 patent/US7674459B2/en active Active
- 2004-12-23 ES ES04815598T patent/ES2390344T3/es active Active
- 2004-12-23 MX MX2015002420A patent/MX361174B/es unknown
- 2004-12-23 LT LTEP20155148.8T patent/LT3718564T/lt unknown
- 2004-12-23 EP EP20155148.8A patent/EP3718564B1/en active Active
- 2004-12-23 PL PL20155148.8T patent/PL3718564T3/pl unknown
- 2004-12-23 SG SG2012070413A patent/SG184774A1/en unknown
- 2004-12-23 KR KR1020137007978A patent/KR20130041373A/ko active Application Filing
- 2004-12-23 LT LTEP14164624.0T patent/LT2805728T/lt unknown
- 2004-12-23 PL PL14164624T patent/PL2805728T3/pl unknown
- 2004-12-23 CA CA2551110A patent/CA2551110C/en active Active
- 2004-12-23 PT PT201551488T patent/PT3718564T/pt unknown
- 2004-12-23 WO PCT/US2004/043501 patent/WO2005062967A2/en active Application Filing
- 2004-12-23 JP JP2006547431A patent/JP4851944B2/ja active Active
- 2004-12-23 JP JP2006547441A patent/JP4943161B2/ja active Active
- 2004-12-23 KR KR1020157014126A patent/KR20150064250A/ko not_active Application Discontinuation
- 2004-12-23 PL PL04815598T patent/PL1711528T3/pl unknown
- 2004-12-23 KR KR1020127001379A patent/KR20120020203A/ko active Application Filing
- 2004-12-23 WO PCT/US2004/043541 patent/WO2005062972A2/en active Application Filing
- 2004-12-23 ES ES04815562T patent/ES2385038T3/es active Active
- 2004-12-23 FI FIEP20155148.8T patent/FI3718564T3/fi active
- 2004-12-23 EP EP10178487A patent/EP2351584A1/en not_active Withdrawn
- 2004-12-23 US US10/583,927 patent/US8067199B2/en active Active
- 2004-12-23 DK DK20155148.8T patent/DK3718564T3/da active
- 2004-12-23 SI SI200431888T patent/SI1703893T1/sl unknown
- 2004-12-23 SI SI200431935T patent/SI1711528T1/sl unknown
- 2004-12-23 CN CN201410077001.6A patent/CN104013957B/zh active Active
- 2004-12-23 DK DK04815598.0T patent/DK1711528T3/da active
- 2004-12-23 SG SG10201404273QA patent/SG10201404273QA/en unknown
- 2004-12-23 CN CNA2004800388204A patent/CN1898264A/zh active Pending
-
2006
- 2006-05-31 IL IL176042A patent/IL176042A/en active IP Right Grant
-
2007
- 2007-01-25 JP JP2007015642A patent/JP2007161724A/ja active Pending
- 2007-11-30 HK HK07113106.7A patent/HK1108007A1/xx unknown
-
2008
- 2008-09-29 US US12/240,604 patent/US8088618B2/en active Active
-
2010
- 2010-01-14 US US12/687,637 patent/US8318160B2/en active Active
- 2010-10-15 JP JP2010233095A patent/JP2011042669A/ja active Pending
-
2011
- 2011-05-18 JP JP2011111913A patent/JP2011200242A/ja not_active Withdrawn
- 2011-10-18 US US13/275,684 patent/US8734801B2/en active Active
- 2011-10-18 US US13/275,658 patent/US8734797B2/en active Active
- 2011-11-30 US US13/308,186 patent/US9067994B2/en active Active
-
2012
- 2012-05-03 HR HRP20120376TT patent/HRP20120376T1/hr unknown
- 2012-05-31 CY CY20121100496T patent/CY1113009T1/el unknown
- 2012-06-05 RU RU2012123148/10A patent/RU2012123148A/ru unknown
-
2013
- 2013-08-20 US US13/971,394 patent/US9605065B2/en active Active
-
2014
- 2014-04-23 IL IL232210A patent/IL232210A0/en unknown
-
2015
- 2015-02-27 HK HK15102008.9A patent/HK1201457A1/xx unknown
- 2015-05-23 HK HK15104923.7A patent/HK1204288A1/xx unknown
-
2017
- 2017-09-29 US US15/721,570 patent/US20180251538A1/en not_active Abandoned
-
2019
- 2019-11-13 US US16/682,773 patent/US11434287B2/en active Active
-
2020
- 2020-02-13 RU RU2020106818A patent/RU2752833C1/ru active
- 2020-04-14 HR HRP20200592TT patent/HRP20200592T1/hr unknown
- 2020-04-28 CY CY20201100385T patent/CY1122817T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2012123148A (ru) | Новые анти-il-13 антитела и их использование | |
RU2013123927A (ru) | ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С α-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4α)-173 | |
US9718884B2 (en) | Anti-TNF-/anti-IL-23 bispecific antibodies | |
JP2016539176A5 (ru) | ||
CN104774266A (zh) | 白介素-13结合蛋白 | |
JP2021101720A5 (ru) | ||
JP2018500883A5 (ru) | ||
RU2016108828A (ru) | Способы и композиции, включающие очищенные рекомбинантные полипептиды | |
RU2009134227A (ru) | Связывающие элементы для молекул ige | |
RU2015141529A (ru) | Антитела и биспецифические антитела к il-4 и их применение | |
TW201920675A (zh) | 抗il-33抗體及其用途 | |
CN107488227A (zh) | 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用 | |
MX2012004086A (es) | Molecula de union especifica al rsv. | |
US20200399382A1 (en) | Combined antagonists against il-5/il-5r and either il-4/il-4r or il-13/il-13r | |
RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
RU2009120202A (ru) | Способы и композиции для лечения и мониторинга лечения связанных с il-13 расстройств | |
JP2020505927A5 (ru) | ||
EP3670533A1 (en) | Il-17a binding agent and uses thereof | |
RU2020133229A (ru) | Антитела к klk5 и способы применения | |
US10954292B2 (en) | Anti-PACAP antibody | |
WO2022127793A1 (zh) | 呼吸道合胞病毒特异性结合分子 | |
CN112638940B (zh) | 抗-il-25抗体及其用途 | |
JP6592600B2 (ja) | 抗cgrp/抗il−23二重特異性抗体及びその使用 | |
CN104628850B (zh) | Rsv-特异性结合分子 | |
CN105037548B (zh) | 抗人白介素-6受体β链单克隆抗体、其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HE9A | Changing address for correspondence with an applicant |